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 Chapter 1 
 Interfollicular Epidermal Stem Cells: 
Boosting and Rescuing from Adult Skin 
 Mariana  T.  Cerqueira ,  Ana  M.  Frias ,  Rui  L.  Reis , and  Alexandra  P.  Marques 
 Abstract 
 Epidermal stem cells isolation struggle remains, mainly due to the yet essential requirement of well-de fi ned 
approaches and markers. The herein proposed methodology integrates an assemblage of strategies to 
accomplish the enrichment of the interfollicular epidermal stem cells multipotent fraction and their subse-
quent separation from the remaining primary human keratinocytes culture. Those include rapid adherence 
of freshly isolated human keratinocytes to collagen type IV through the  β 1-integrin ligand and Rho-
Associated Protein Kinase Inhibitor Y- 27632 administration to the cultures, followed by an immunomag-
netic separation to obtain populations based in the combined CD49f bri /CD71 dim expression. Flow 
cytometry is the supporting method to analyze the effect of the treatments over the expression rate of early 
epidermal markers keratins19/5/14 and in correlation to CD49f bri /CD71 dim subpopulations. The step-
by-step methodology herein described indulges the boosting and consecutive puri fi cation and separation 
of interfollicular epidermal stem cells from human keratinocytes cultures. 
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 Human keratinocytes (hKC) have a limited lifespan in culture that 
constraints their proliferative capacity and consequently their clini-
cal potential. The long-term function of the skin equivalents gen-
erated in a Regenerative Medicine context can be limited by the 
length of time needed to obtain epithelial sheets in vitro, during 
which patient is highly susceptible to infection, and also by exten-
sive culture that may lead to terminal differentiation of the hKC to 
be grafted, thus compromising its success. Therefore, the use of 
epidermal stem cells (EpSCs) that play an important role in cellular 
regeneration, wound healing, and neoplasm formation  ( 1 ) for this 
purpose enlarges the possibility of providing an alternative and 
clinically relevant active source of biological material. 
 Despite a wide effort among stem cells biologists community 
 ( 2– 6 ) , EpSCs isolation dif fi culty remains, mainly due to the 
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insuf fi ciency of molecular markers that distinguish these cells from 
other proliferative cells within skin basal layer, highlighting the 
need for de fi ning approaches and a panel of markers to obtain speci fi c 
and well-characterized cell populations. P63 is abundantly expressed 
by holoclones and therefore recognized as being also present in 
EpSCs playing an important role in morphogenesis and in the 
expression pattern of the cultures  ( 7 ) . It has been also proposed 
that EpSCs exhibit a characteristic keratin pro fi le that includes the 
typical K5 and K14 expression of the basal layer but not of K1/10 
of the suprabasal layer cells. K19 appears also as an EpSCs-associated 
marker as it is expressed by cells present in the skin hair follicles 
bulge and in the deep epidermal rete ridges within thicker epider-
mis, being also expressed by a subpopulation of hKC in the human 
basal layer during proliferative lateral skin expansion  ( 8 ) . 
 Interestingly, the molecules related with cell-substratum adhe-
sion are naturally meaningful as potential EpSCs markers, sup-
ported by the hypothesis that EpSCs require strong adherence to 
the basement membrane to maintain their stem cell characteristics 
or their position in the stem cell niche.  ( 9 ) . b 1-integrin was  fi rstly 
identi fi ed in highly proliferating KC (holoclones) and was used to 
distinguish EpSCs and other basal cells  ( 5 ) . However, subsequent 
studies revealed that the majority of the cells of the basal layer in 
the human epidermis, EpSCs, and transient amplifying cells exhibit 
the expression of beta 1 integrin  ( 10 ) and other putative markers 
such as the combination of CD49f ( α 6-integrin) and CD71 (trans-
ferrin receptor)  ( 5 ) . Human epidermal cells have been thus divided 
into three different subsets,  α 6 bri CD71 dim ,  α 6 bri CD71 bri , and  α 6 dim 
expressing cells, the  fi rst being those with the highest proliferation 
rate and capability of long-term epidermal renewal  ( 11 ) , even at a 
limited dilution. 
 Despite the high importance of EpSCs, they constitute between 
1% and 10% of the basal layer cells and, independently of the stan-
dardization of a characteristic panel of markers, boosting this popu-
lation in culture through enrichment methods is a major demand. 
The involvement of Rho-Associated Protein Kinase (Rock) in tissue 
homeostasis, namely in the epidermis, is already recognized. 
Regardless of the unconsciousness of the exact timing of events, the 
key role that Rock plays in determining hKC fate was clearly dem-
onstrated. By blocking Rock function, an inhibition of hKc termi-
nal differentiation and an increase in cell proliferation was observed 
 ( 12 ) . It has also been shown that Rock inhibitor (Rocki) leads to an 
increased number of hKC in primary cultures that can survive and 
grow forming healthy colonies, thus suggesting its effect in boost-
ing the cells exhibiting stem cell behavior  ( 13 ) yet retaining the 
ability to differentiate and to form a strati fi ed epithelium in ade-
quate organotypic models  ( 14 ) . The herein proposed methodology 
describes an assemblage of strategies to accomplish enrichment and 
further puri fi cation of the EpSCs multipotent fraction present in 
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hKC primary cultures. The procedure combines the rapid adherence 
of primary hKC to  β 1-integrin ligand in collagen type IV and the 
administration of Rho-Associated Protein Kinase (Rock) Inhibitor 
Y- 27632 to the culture, together with subsequent immunomag-
netic separation of subpopulations combining CD49f bri /CD71 dim 
expression. 
 
 Petri dishes (Greiner Bio One, Cat. No. 391-2080). 
 Forceps (RSG, Cat. No. 311.105). 
 Surgical scissors (RSG, Cat. No. 101.130). 
 Cell culture  fl asks (75 cm 2 , 150 cm 2 ) (BD Falcon, Cat. No. 353136, 
353028). 
 6-well culture plates (BD Falcon, Cat. No. 353224). 
 15 mL Falcon tubes (BD Falcon, Cat. No. 352097). 
 50 mL Falcon tubes (BD Falcon, Cat. No. 352070). 
 Flow cytometry tubes (BD Falcon, Cat. No. 352052). 
 Pipettes (Corning Science Products, Cat. No. 4489). 
 Cell strainers of 100  μ m pore size (BD Falcon, Cat. No. 352360). 
 Eppendorf tubes 1.5 mL (Laborspirit, Cat. No. 200400P). 
 DynaMag™-2 magnet (Invitrogen, Cat. No. 123-21D). 
 0.22  μ m pore membrane  fi lters (Sarsted, Cat. No. 83.1823.101). 
 Phosphate buffer saline (PBS) (Sigma, Cat. No. P4417). 
 Distilled water (diH 2 O). 
 Antibiotic/antimycotic solution (Gibco, Cat. No. 15240062). 
 Dispase (BD Biosciences, Cat. No. 354235). 
 Trypsin–EDTA (Gibco, Cat. No. 25300-062). 
 Keratinocyte Serum Free Medium (KSFM) Kit with  l -Glutamine, 
EGF, and BPE (Gibco, Cat. No. 17005-075). 
 Y-27632 dihydrochloride monohydrate (Sigma, Cat. No. Y0503). 
 Acetic acid (vWR, Cat. No. 20104.334). 
 Human placenta collagen type IV (Sigma, Cat. No. C5533). 
 Bovine serum albumin (BSA) (Sigma, Cat. No. A2153). 
 Dynabeads M-450 Epoxy (Life Technologies, Cat. No. 14011). 
 Sodium phosphate (Sigma, S0876). 
 Permeabilization buffer (10×) (eBioScience, Cat No. 00-8333). 
 CD49f-APC antibody (eBioscience, Cat. No. 17-0495-82). 
2  Materials
 2.1  Labware 
( see  Note 1 )
 2.2  Reagents
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 CD71-PE antibody (BD Biosciences, Cat. No. 555537). 
 Cytokeratin 19-AF488 antibody (ExBio, Cat. No. A4-120-C100). 
 Cytokeratin 14-FITC antibody (AbD Serotec, MCA890F). 
 Keratin 5 antibody (Covance, Cat. No. PRB-160P). 
 Alexa Fluor 488 Goat anti-Rabbit (Invitrogen, Cat. No. A-11008). 
 Formaldehyde (vWR, Cat. No. ALFA33314K2). 
 Sodium azide (Sigma, Cat. No. 13412). 
  1.  Dispase stock solution (25 U/mL) : dilute dispase, 1:2 in PBS 
( see  Note 2 ). 
  2.  Collagen IV stock solution (1 mg/mL) : Add 5 mL of 0.25% acetic 
acid and let to dissolve overnight at 4°C ( see  Notes 2 and  3 ). 
  3.  Rocki stock solution (1 mM): Reconstitute 1 mg of Y-27632 
dihydrochloride monohydrate in 2.96 mL of diH 2 O. 
  4.  Dynabeads buffer 1 : prepare a buffer of 0.1 M Sodium phos-
phate in diH 2 O and adjust pH to 7.4–8.0 ( see  Note 4 ) 
  5.  Dynabeads buffer 2 : make a 0.1% BSA solution in PBS and 
adjust the pH to 7.4. 
  6.  Coating of immunomagnetic beads with CD71 and CD49f 
antibodies ( see  Note 5 )
 6.1  Transfer 10  μ L of dynabeads to an eppendorf tube. 
 6.2  Place the tube in a magnet for a minute and discard the 
supernatant. Remove the tube from the magnet. 
 6.3  Resuspend the beads in 50  μ L of Dynabeads buffer 1 and 
add 4  μ L of CD71 or 2  μ L of CD49f antibody. 
 6.4  Incubate for 16–24 h at room temperature with gentle 
tilting and rotation. 
 6.5  Repeat  step 6.2 and resuspend beads in Dynabeads buffer 2. 
  7.  Permeabilization buffer: Dilute permeabilization buffer (10×) 
in diH 2 O to obtain a 1× working solution, store at 4°C. 
  8.  Labeling buffer: Prepare a 3% BSA solution in PBS. 
  9.  Acquisition buffer: Make a 1% formaldehyde and 0.1% Sodium 
azide solution in PBS,  fi lter (0.22  μ m pore membrane), and 
store at RT. 
  10.  Antibiotic/antimycotic solution : Make a 1% antibiotic solution 
in PBS 
  11.  Dispase working solution (2.5 U/mL): Dilute 1:10 of stock dis-
pase solution in 1% solution of antibiotic/antimycotic in PBS 
  12.  Rocki working solution (10  m M): Dilute Rocki stock solution 
(1 mM) 1:100 in KSFM, in order to have KSFM supplemented 
with 10  μ M Rocki. 
 2.3  Reagents Setup
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  1.  Remove the exceeding fat tissue from the dermis with scissors 
and scalpel. 
  2.  Wash the skin samples with  antibiotic/antimycotic solution 
(±20 s). 
  3.  Cut skin into 0.5 cm 2 pieces. 
 Incubate skin pieces in dispase working solution (2.5 U/mL) over-
night at 4°C in a 250 mL  fl ask. 
 After incubation place the skin samples on a Petri dish and peel 
off epidermis from dermis using two pairs of forceps. 
  1.  Place epidermis (dermal side up) in a new Petri dish. 
  2.  Add 0.05% trypsin–EDTA. 
  3.  Incubate the samples at 37°C for 5–7 min. 
  4.  Add an equal amount of KSFM. 
  5.  Scrape of cells carefully with a cell scraper. 
  6.  Pipette rigorous up and down several times. 
  7.  Poor cell suspension trough a 100  μ m pore size cell strainer 
into a 50 mL Falcon tube. 
  8.  Wash with PBS, passing the liquid through the 100  μ m pore 
size cell strainer. 
  9.  Centrifuge for 5 min at 290 ×  g. 
  10.  Wash pellet with 5 mL of PBS. 
  11.  Poor cells trough a 100  μ m pore size cell strainer into a 50 mL 
Falcon tube. 
  12.  Centrifuge for 4 min at 290 ×  g . 
  13.  Resuspend cell pellet (hKC) in KSFM. 
  1.  Coat tissue culture surface with collagen IV, by incubating 
5  μ g/cm 2 at 37°C, for at least 1 h ( see  Note 3 ). 
  2.  Wash with PBS. 
  3.  Plate 2 × 10 4 hKC/cm 2 in KSFM. 
  4.  Change medium every 2–3 days and keep the culture until 80% 
con fl uent. 
  1.  Plate 2 × 10 4 cells/cm 2 in Rocki working solution (10  μ M). 
  2.  Change medium every 2–3 days; keep them in culture until 
80% con fl uent. 
  1.  Perform steps 1 and 2 described in section 3.2.1. 
  2.  Proceed as described in section 3.2.2 . 
 3  Methods
 3.1  Isolation of 
Human Keratinocytes 
from Adult Skin
 3.1.1  Processing Human 
Skin
 3.1.2  Epidermal–Dermal 
Separation by Dispase
 3.1.3  Isolation of Human 
Keratinocytes: Digestion of 
Epidermis with Trypsin
 3.2  EpSCs 
Enrichment Strategies 
( see  Note 6 )
 3.2.1  Rapid Adherence 
to Collagen IV
 3.2.2  Rock Inhibitor
 3.2.3  Combined 
Approach
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 An intermediate analysis of a fraction of the obtained cells after 
each treatment should be performed in order to assess the effect in 
the increased fraction of interest—EpSCs fraction. Therefore in 
this section a  fl ow cytometry protocol using a combination of 
CD49f-APC and CD71-PE markers is described.
    1.  Harvest the adherent cells cultured under the described condi-
tions with trypsin–EDTA. 
  2.  Transfer cells to a 15 mL falcon tube and add labeling buffer 
up to 10 mL. 
  3.  Centrifuge cell suspension at 200 ×  g for 5 min. 
  4.  Count cells using a hemocytometer. 
  5.  Discard supernatant and resuspend cell pellet to a concentra-
tion of 0.5–10 6 cells/mL in fresh labeling buffer. 
  6.  Add 100  μ L of cell suspension to each  fl ow cytometry tube 
( see  Note 7 ). 
  7.  Add 4  μ L of CD71-PE and 2  μ L CD49f-APC antibodies; 
reserve one tube per condition without antibody as control. 
  8.  Incubate 30 min at room temperature. 
  9.  Wash by adding 2 mL of PBS per tube and centrifuge at 250 ×  g 
for 3 min. 
  10.  Resuspend cell pellets in 500  μ L of acquisition buffer. 
  11.  Acquire data in  fl ow cytometer. 
  12.  Analyze simultaneous expression of CD71 and CD49f (Fig.  1 ). 
  1.  Wash CD71 coated beads by placing the tubes in a magnet for 
1 min, discarding the supernatant and adding 1 mL of 
Dynabeads buffer 2, twice. 
  2.  Incubate the cells harvested on Subheading  3.3 ,  step 1 and 
resuspended in Dynabeads buffer 2 with the washed CD71 
beads for 30 min at 2–8°C with gentle tilting and rotation. 
  3.  Place the tubes in a magnet for 2 min. 
  4.  Transfer the supernatant containing the unbound cells to a 
fresh 15 mL Falcon tube (CD71 − cell fraction). 
  5.  Count cells using a hemocytometer. 
  6.  Plate 2 × 10 4 cells/cm 2 in new tissue culture vessels/ fl asks with 
the correspondent treatments (described in Subheading  3.2 ). 
  7.  Culture cells until 80% con fl uent by changing medium 2–3 days. 
  1.  Harvest CD71 − cells with trypsin–EDTA and resuspend them 
in Dynabeads buffer 2. 
  2.  Wash CD49f coated beads by placing the tubes in a magnet for 
1 min, discarding the supernatant and adding 1 mL of 
Dynabeads buffer 2, twice. 
 3.3  Intermediate 
Analysis
 3.4  CD71 − /CD49f + 
Rescuing: 
Immunomagnetic 
Selection
 3.4.1  Depletion of CD71 + 
Cells
 3.4.2  Positive Selection 
of CD49f + Cells Among 
CD71 − Population
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  3.  Incubate CD71 − cells for 20 min at 2–8°C with gentle tilting 
and rotation. 
  4.  Place the tubes in a magnet for 2 min. 
  5.  Discard the supernatant and gently wash the bead-bounded 
cells, four times, by adding 1 mL of Dynabeads buffer 2. 
  6.  Place the tubes in the magnet for 1 min and discard the 
supernatant. 
  7.  Resuspend the cells in fresh KSFM. 
  8.  Plate 2 × 10 4 cells/cm 2 in new tissue culture vessels/ fl asks with 
the correspondent treatments (described in Subheading  3.2 ) 
for further cell expansion and analysis. 
 The analysis of the expression of the early epidermal markers on 
the obtained cell fraction by  fl ow cytometry is advisable to validate the 
success of the employed strategies. Thus, this section comprises 
the protocol for identifying the expression of the intracellular 
markers using Cytokeratin 19-AF488 and Cytokeratin 14-FITC, 
and Keratin 5, respectively by direct and indirect staining. 
 Follow the protocol from Subheading  3.3 ,  steps 1 – 11 , using 5  μ L 
of Cytokeratin 19-AF488 and 4  μ L of Cytokeratin 14-FITC in 
separate tubes. 
 3.5  Analysis
 3.5.1  Direct Staining
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 Fig. 1  Dot plots of CD49f/CD71 staining on human keratinocytes isolated from the same human sample and 
cultured without any treatment ( a ) and after EpSCs enrichment with Rocki ( b ), showing an increase of the 
population of interest by the differential expression of CD49f bri /CD71 dim (6.20% in  a and 10.37% in  b ) 
 
8 Mariana T. Cerqueira et al.
  1.  Follow the protocol from Subheadings  3.3 ,  steps 1 – 6 . 
  2.  Incubate cells with 200  μ L of permeabilization buffer for 
10 min at RT. 
  3.  Centrifuge for 5 min at 250 ×  g and remove supernatant. 
  4.  Resuspend cells in 200  μ L of keratin 5 antibody diluted 1:500 
in labeling buffer. 
  5.  Incubate for 1 h at room temperature. 
  6.  Wash by adding 2 mL of PBS, centrifuge at 250 ×  g for 5 min, 
and remove supernatant. 
  7.  Resuspend cells in 200  μ L of Alexa- fl uor-labeled secondary 
antibody diluted 1:500 in labeling buffer. 
  8.  Incubate 45 min at 4°C protected from light. 
  9.  Wash by adding 2 mL of PBS, centrifuge at 250 ×  g for 5 min, 
and remove supernatant. 
  10.  Resuspend cell pellets in 500  μ L of acquisition buffer. 
  11.  Acquire data in  fl ow cytometer (Fig.  2 ). 
 3.5.2  Indirect Staining
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 Fig. 2  Expression  fl uorescence pro fi le of Keratin 5 (early epidermal marker) in both CD71-/ α 6+ cells (25.45%) 
( a ) and CD71-/ α 6- (17.42%) ( b ), showing the higher expression of K5 in the fraction of interest, thus illustrat-
ing its early differentiation stage 
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  1.  All the labware has to be sterilized prior use. 
  2.  It is recommended to make aliquots that should be kept at 
−20°C, avoiding repeated freeze-thawing. 
  3.  Coating with collagen IV can be previously performed incu-
bating solution overnight at 4°C, without drying. 
  4.  Alternatively, a solution of 0.1 M sodium borate sulfate in 
diH 2 O, pH 7.4–8, can be used as buffer 1. 
  5.  This protocol is adapted from the section “coupling of ligands 
to dynabeads” of the Dynabeads m-450 Epoxy manufacturer’s 
instructions. 
  6.  Cells cultured, in these different treatments, present distinct 
adherence and proliferation rates. No speci fi c treatment, in 
which cells are cultured in noncoated plates and in KSFM, 
should be performed as a control. hKC cultured in Rocki and 
No treatment take almost 1 week to  fi rst adhere. 
  7.  The remaining cells should be used as described in 
Subheading  3.4 and kept in culture for comparison purposes in 
the end of the experiment. 
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